BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34946287)

  • 1. A Pattern of Care Report on the Management of Patients with Squamous Cell Carcinoma of the Anus-A Study by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Tumors Study Group.
    Franco P; Chiloiro G; Montesi G; Montrone S; Arcelli A; Comito T; Arcadipane F; Caravatta L; Macchia G; Lupattelli M; Niespolo MR; Munoz F; Palazzari E; Krengli M; Valvo F; Gambacorta MA; Genovesi D; Mantello G
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946287
    [No Abstract]   [Full Text] [Related]  

  • 2. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
    Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
    Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of anal cancer patients - a pattern of care analysis in German-speaking countries.
    Martin D; von der Grün J; Rödel C; Fokas E
    Radiat Oncol; 2020 May; 15(1):122. PubMed ID: 32450863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
    Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
    J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
    Belgioia L; Vagge S; Agnese D; Garelli S; Murialdo R; Fornarini G; Chiara S; Gallo F; Bacigalupo A; Corvò R
    World J Gastroenterol; 2015 Oct; 21(37):10688-96. PubMed ID: 26457030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
    Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of the Primary Tumor in Anal Canal Cancers.
    Glynne-Jones R; Rao S
    Surg Oncol Clin N Am; 2017 Jan; 26(1):73-90. PubMed ID: 27889038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
    Thind G; Johal B; Follwell M; Kennecke HF
    Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
    Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitive chemoradiotherapy for anal canal cancer: single-center experience.
    Tachibana I; Nishimura Y; Inada M; Fukuda K; Ishikawa K; Nishikawa T; Yokokawa M; Nakamatsu K; Kanamori S; Hida JI
    Int J Clin Oncol; 2018 Dec; 23(6):1121-1126. PubMed ID: 29992389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
    Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
    Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma.
    Gordeyev SS; Rasulov AO; Gorbounova VA; Tkachev SI; Glebovskaya VV; Fedyanin MY; Besova NS; Surayeva YE
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):623-629. PubMed ID: 28766008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
    de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
    Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study.
    Franco P; De Bari B; Arcadipane F; Lepinoy A; Ceccarelli M; Furfaro G; Mistrangelo M; Cassoni P; Valgiusti M; Passardi A; Casadei Gardini A; Trino E; Martini S; Iorio GC; Evangelista A; Ricardi U; Créhange G
    Radiat Oncol; 2018 Sep; 13(1):172. PubMed ID: 30201015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].
    Pang XL; Liu S; Liu YP; Chen HY; He F; Zheng J; Wan XB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):977-983. PubMed ID: 34823298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.